5-Fluorouracil (5-FU) Toxicity & Chemotherapeutic Response (DPYD Variant Analysis)

Overview

The 5-Fluorouracil (5-FU) Toxicity & Chemotherapeutic Response (DPYD Variant Analysis) test identifies genetic variants in the DPYD (Dihydropyrimidine Dehydrogenase) gene that affect the body's ability to break down 5-Fluorouracil (5-FU) and Capecitabine, two commonly used chemotherapy drugs. Detecting these variants helps predict the risk of severe drug toxicity and supports personalized chemotherapy dosing.

Why is this Test Done?

This test is recommended to:

• Assess the risk of severe 5-FU or Capecitabine toxicity before treatment.
• Identify DPYD gene variants associated with reduced enzyme activity.
• Guide personalized chemotherapy dosing for safer treatment.
• Minimize life-threatening adverse drug reactions.
• Improve treatment outcomes through pharmacogenomic testing.

Symptoms of 5-FU Toxicity

Patients with reduced DPYD enzyme activity may experience:

• Severe diarrhea
• Mouth ulcers (mucositis)
• Persistent nausea and vomiting
• Extreme fatigue
• Low white blood cell count (neutropenia)
• Increased risk of infections
• Hand-foot syndrome
• Severe bone marrow suppression

Who Should Get Tested?

• Patients scheduled to receive 5-Fluorouracil (5-FU) or Capecitabine chemotherapy.
• Individuals with a family history of severe chemotherapy toxicity.
• Cancer patients requiring personalized chemotherapy planning.
• Patients who experienced unexpected toxicity during previous fluoropyrimidine therapy.

Sample Required

• Sample Type: Peripheral Blood
• Container: EDTA Tube

Preparation

• No fasting is required.
• Inform your doctor about current medications and ongoing treatments.
• This is a one-time genetic test performed before chemotherapy whenever possible.

Benefits of DPYD Variant Analysis

• Identifies patients at high risk of severe drug toxicity.
• Enables personalized chemotherapy dose adjustments.
• Helps avoid serious treatment-related complications.
• Supports precision oncology and safer cancer care.
• Improves confidence in chemotherapy treatment planning.

Interpretation

• No Clinically Significant Variant Detected: Normal DPYD enzyme activity; standard dosing may be considered.
• Variant Detected: Reduced DPYD enzyme activity; dose reduction or alternative therapy may be recommended based on clinical guidelines.

Note: Test results should always be interpreted by an oncologist or qualified healthcare professional in conjunction with clinical findings and treatment guidelines.